BR112015021324A2 - derivados de 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de atividade de quinase - Google Patents

derivados de 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de atividade de quinase

Info

Publication number
BR112015021324A2
BR112015021324A2 BR112015021324A BR112015021324A BR112015021324A2 BR 112015021324 A2 BR112015021324 A2 BR 112015021324A2 BR 112015021324 A BR112015021324 A BR 112015021324A BR 112015021324 A BR112015021324 A BR 112015021324A BR 112015021324 A2 BR112015021324 A2 BR 112015021324A2
Authority
BR
Brazil
Prior art keywords
imidazol
pyrimidin
piperidin
kinase activity
amine derivatives
Prior art date
Application number
BR112015021324A
Other languages
English (en)
Inventor
Goutopoulos Andreas
R Huck Bayard
Lan Ruoxi
Chen Xiaoling
Xiao Yufang
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112015021324A2 publication Critical patent/BR112015021324A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

resumo patente de invenção: "derivados de 6-[4-(1h-imidazol-2-il) piperidin-1-il]pirimidin-4-amina como moduladores de atividade de quinase". a invenção fornece aminas heterocíclicas de acordo com a fórmula (i), sua fabricação e uso para tratamento de doenças hiperproliferativas, tal como câncer. fórmula (l):
BR112015021324A 2013-03-11 2014-03-10 derivados de 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de atividade de quinase BR112015021324A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776440P 2013-03-11 2013-03-11
PCT/US2014/022479 WO2014143612A1 (en) 2013-03-11 2014-03-10 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity

Publications (1)

Publication Number Publication Date
BR112015021324A2 true BR112015021324A2 (pt) 2017-07-18

Family

ID=50440836

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021324A BR112015021324A2 (pt) 2013-03-11 2014-03-10 derivados de 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de atividade de quinase

Country Status (17)

Country Link
US (2) US9458134B2 (pt)
EP (1) EP2970201B1 (pt)
JP (1) JP6483656B2 (pt)
KR (1) KR20150124957A (pt)
CN (1) CN105209454A (pt)
AR (1) AR095202A1 (pt)
AU (1) AU2014228385B2 (pt)
BR (1) BR112015021324A2 (pt)
CA (1) CA2902755C (pt)
ES (1) ES2746756T3 (pt)
HK (1) HK1218756A1 (pt)
IL (1) IL240875B (pt)
MX (1) MX370448B (pt)
RU (1) RU2674261C2 (pt)
SG (2) SG11201505999VA (pt)
WO (1) WO2014143612A1 (pt)
ZA (1) ZA201505749B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143612A1 (en) * 2013-03-11 2014-09-18 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
EP3105224A1 (en) * 2014-02-11 2016-12-21 Merck Patent GmbH Pyrimidine imidazole amines as modulators of kinase activity
EP3125935B1 (en) * 2014-04-03 2019-10-23 Merck Patent GmbH Combinations of cancer therapeutics
TWI732187B (zh) * 2016-05-20 2021-07-01 日商大鵬藥品工業股份有限公司 新穎5H-吡咯并[2, 3-d]嘧啶-6(7H)-酮衍生物
CN110922354B (zh) * 2019-12-12 2023-05-02 丽水绿氟科技有限公司 一种1-r-3-氟哌啶-4-羧酸的化学拆分制备方法及其产物
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7754722B2 (en) * 2002-09-20 2010-07-13 Merck Serono Sa Piperazine derivatives and methods of use
AU2004230841A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2005033086A1 (en) 2003-09-30 2005-04-14 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2541989C (en) 2003-10-24 2013-10-01 Exelixis, Inc. P70s6 kinase modulators and method of use
KR20060117329A (ko) 2003-11-21 2006-11-16 노파르티스 아게 단백질 키나제 저해제로서의 1ｈ-이미다조퀴놀린 유도체
TR200808208T1 (tr) 2003-12-09 2008-12-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi
GB0403606D0 (en) * 2004-02-18 2004-03-24 Novartis Ag Organic compounds
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
KR20110075015A (ko) * 2008-11-11 2011-07-05 일라이 릴리 앤드 캄파니 Ｐ70 ｓ6 키나제 억제제 및 ｅｇｆｒ 억제제 조합 요법
AR074072A1 (es) * 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
BRPI0921840A2 (pt) * 2008-11-11 2018-10-09 Lilly Co Eli produto compreendendo o composto inibidor de p70 s6 quinase e inibidor de mtor, composto inibidor de p70 s6 quinase e uso do mesmo
DK2396307T3 (en) 2009-02-11 2015-01-12 Merck Patent Gmbh NOVEL AMINO-azaheterocyclic carboxamides
EA020151B1 (ru) * 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CA2803387C (en) * 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
JP5897590B2 (ja) 2010-11-24 2016-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナゾリンカルボキサミドアゼチジン
SG194219A1 (en) * 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
JP6162694B2 (ja) * 2011-07-18 2017-07-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ベンズアミド類
MX347241B (es) * 2011-09-12 2017-04-20 Merck Patent Gmbh Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
SI2755965T1 (sl) * 2011-09-12 2017-12-29 Merck Patent Gmbh Novi imidazolni amidi kot modulatorji kinazne aktivnosti
PT2794571T (pt) * 2011-12-22 2017-02-07 Merck Patent Gmbh Novas carboxamidas heterocíclicas como moduladores da atividade de quinase
US10227357B2 (en) * 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP6280130B2 (ja) * 2012-11-16 2018-02-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
WO2014143612A1 (en) * 2013-03-11 2014-09-18 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
EP3105224A1 (en) * 2014-02-11 2016-12-21 Merck Patent GmbH Pyrimidine imidazole amines as modulators of kinase activity
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor

Also Published As

Publication number Publication date
IL240875B (en) 2020-08-31
ES2746756T3 (es) 2020-03-06
US20160016936A1 (en) 2016-01-21
WO2014143612A1 (en) 2014-09-18
MX2015011660A (es) 2015-12-16
US20160361316A1 (en) 2016-12-15
JP2016512509A (ja) 2016-04-28
CA2902755C (en) 2021-02-16
MX370448B (es) 2019-12-13
SG10201900954SA (en) 2019-02-27
RU2015143160A (ru) 2017-04-18
JP6483656B2 (ja) 2019-03-13
HK1218756A1 (zh) 2017-03-10
RU2015143160A3 (pt) 2018-03-01
AR095202A1 (es) 2015-09-30
KR20150124957A (ko) 2015-11-06
SG11201505999VA (en) 2015-08-28
AU2014228385B2 (en) 2018-08-09
EP2970201A1 (en) 2016-01-20
US9867826B2 (en) 2018-01-16
CA2902755A1 (en) 2014-09-18
CN105209454A (zh) 2015-12-30
EP2970201B1 (en) 2019-06-19
ZA201505749B (en) 2017-01-25
US9458134B2 (en) 2016-10-04
RU2674261C2 (ru) 2018-12-06
IL240875A0 (en) 2015-10-29
AU2014228385A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
BR112014005468A2 (pt) derivados de aminopiridina para uso como moduladores de atividade quinase
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX368066B (es) Derivados de quinazolin-4-ona sustituida.
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
BR112015000399A2 (pt) derivados de pirazolil pirimidina
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
PH12015502047A1 (en) Novel pyrimidine and pyridine compounds and their usage
CO6680717A2 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
UA110880C2 (uk) Заміщені амідином бета-лактами, їх одержання та застосування як антибактеріальних засобів
MX2015010125A (es) Derivados de piridazinona-amidas.
BR112015021324A2 (pt) derivados de 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de atividade de quinase
GEP201706778B (en) Pyridinyl and fused pyridinyl triazolone derivatives
MY171831A (en) Novel fused pyrimidine compound or salt thereof
NZ709153A (en) Pyrimidinone derivatives having human neutrophil elastase inhibitory activity
BR112014005554A2 (pt) aminas de imidazol como moduladores de atividade de quinase
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
PH12015500399A1 (en) Azaindolines
MX2015012386A (es) Inhibidores de la cinasa cdk9.
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
AR092772A1 (es) Derivado de 7-azaindol
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL